Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE

Journal of Clinical Oncology

Volumn 29, Issue 11, 2011, Pages 1495-1501

  Grunberg, Steven ^{a,b,c,d,e,f,g}   Chua, Daniel ^{a,b,c,d,e,f,g}   Maru, Anish ^{a,b,c,d,e,f,g}   Dinis, José ^{a,b,c,d,e,f,g}   DeVandry, Suzanne ^{a,b,c,d,e,f,g}   Boice, Judith A ^{a,b,c,d,e,f,g}   Hardwick, James S ^{a,b,c,d,e,f,g}   Beckford, Elizabeth ^{a,b,c,d,e,f,g}   Taylor, Arlene ^{a,b,c,d,e,f,g}   Carides, Alexandra ^{a,b,c,d,e,f,g}   Roila, Fausto ^a   Herrstedt, Jørn ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SEAROC Cancer Centre   (India)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^e MERCK RESEARCH LABORATORIES   (United States)

^f S MARIA HOSPITAL   (Italy)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; FOSAPREPITANT; ONDANSETRON;

ADULT; ADVERSE DRUG REACTION; AGED; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PREVENTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GENITAL TRACT CANCER; HICCUP; HUMAN; HYPERTENSION; INFUSION SITE ERYTHEMA; INFUSION SITE INDURATION; INFUSION SITE PAIN; INFUSION SITE SWELLING; INFUSION SITE THROMBOPHLEBITIS; INJECTION SITE PAIN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; SWELLING; THROMBOPHLEBITIS; TREATMENT RESPONSE; URINARY TRACT CANCER; URINARY TRACT INFECTION; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; ONDANSETRON; TREATMENT OUTCOME; VOMITING;

EID: 79955017477     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.7859     Document Type: Article

References (25)

1. Oo TH, Hesketh PJ: Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2:196-201, 2005 (Pubitemid 40812469)
2. Campos D, Pereira JR, Reinhardt RR, et al: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767, 2001 (Pubitemid 32230878)
3. Herrstedt J, Muss HB, Warr DG, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555, 2005 (Pubitemid 41356171)
4. Herrstedt J, Roila F: Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19:ii110-ii112, 2008 (suppl 2)
5. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving highdose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003 (Pubitemid 46606178)
6. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006 (Pubitemid 46630595)
7. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003 (Pubitemid 36676265)
8. Rapoport BL, Jordan K, Boice JA, et al: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 18: 423-431, 2010
9. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005 (Pubitemid 46179473)
10. Lasseter KC, Gambale J, Jin B, et al.: Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834-840, 2007
11. Chawla SP, Grunberg SM, Gralla RJ, et al: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapyinduced nausea and vomiting. Cancer 97:2290-2300, 2003 (Pubitemid 36444075)
12. Majumdar AK, Howard L, Goldberg MR, et al: Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 46:291-300, 2006 (Pubitemid 43260316)
13. BergströmM, Hargreaves RJ, Burns HD, et al: Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55:1007-1012, 2004 (Pubitemid 38581916)
14. McCrea JB, Majumdar AK, Goldberg MR, et al: Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24, 2003 (Pubitemid 36776172)
15. de Wit R, Herrstedt J, Rapoport B, et al: Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21: 4105-4111, 2003 (Pubitemid 46606177)
16. Miettinen O, Nurminen M: Comparative analysis of two rates. Stat Med 4:213-226, 1985 (Pubitemid 15055349)
17. Hwang IK, Shih WJ, De Cani JS: Group sequential designs using a family of type I error probability spending functions. Stat Med 9:1439-1445, 1990
18. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384, 1985 (Pubitemid 15244935)
19. Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989 (Pubitemid 19089088)
20. Grunberg SM, Deuson RR, Mavros P, et al: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268, 2004 (Pubitemid 38580348)
21. Grunberg SM, Dugan M, Muss H, et al: Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17:589-594, 2009
22. Herrington JD, Jaskiewicz AD, Song J: Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112:2080-2087, 2008 (Pubitemid 351574085)
23. Van Belle S, Lichinitser MR, Navari RM, et al: Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94:3032-3041, 2002 (Pubitemid 34547705)
24. Grunberg SM, Rolski J, Strausz J, et al: Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1) -receptor antagonist, in prevention of chemotherapyinduced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: A randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:549-558, 2009
25. Roila F, Rolski J, Ramlau R, et al: Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 20:1867-1873, 2009